Methicillin-resistant Staphylococcus aureus: Changes in the susceptibility pattern to daptomycin during a 10- year period (2001-2010);Staphylococcus aureus resistente a meticilina: Sensibilidad a la daptomicina a lo largo de un periodo de 10 años (2001-2010)

Revista Espanola de Quimioterapia

Volumn 24, Issue 2, 2011, Pages 107-111

  Picazo, Juan J ^a   Betriu, Carmen ^a   Culebras, Esther ^a   Rodríguez Avial, Iciar ^a   Gómez, María ^a   López Fabal, Fátima ^a  

^a HOSPITAL CLÍNICO SAN CARLOS   (Spain)

Author keywords

Antimicrobial susceptibility; Changes in the susceptibility patterns; Daptomycin; Methicillin resistant Staphylococcus aureus; Multicenter study

Indexed keywords

DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; LINEZOLID; TEICOPLANIN; VANCOMYCIN; ANTIINFECTIVE AGENT;

ARTICLE; DRUG ACTIVITY; HUMAN; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; CROSS INFECTION; DOSE RESPONSE; DRUG EFFECT; ISOLATION AND PURIFICATION; MICROBIOLOGICAL EXAMINATION; MICROBIOLOGY; MULTICENTER STUDY (TOPIC); MULTIDRUG RESISTANCE; RETROSPECTIVE STUDY; SPAIN; STAPHYLOCOCCUS INFECTION;

ANTI-BACTERIAL AGENTS; CROSS INFECTION; DAPTOMYCIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HUMANS; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS; MULTICENTER STUDIES AS TOPIC; RETROSPECTIVE STUDIES; SPAIN; STAPHYLOCOCCAL INFECTIONS;

EID: 80054042637     PISSN: 02143429     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Steinkraus G, White R, Friedrich L. Vancomycin MIC creep in non-vancomycin-intermediate Staphylococcus aureus (VISA), vancomycin-susceptible clinical methicillin-resistant S. aureus (MRSA) blood isolates from 2001-05. J Antimicrob Chemother 2007; 60:788-94.
2. Wang G, Hindler JF, Ward KW, Bruckner DA. Increased vancomycin MICs for Staphylococcus aureus clinical isolates from a university hospital during a 5-year period. J Clin Microbiol 2006; 44:3883-6.
3. Deresinski S. Vancomycin heteroresistance and methicillin-resistant Staphylococcus aureus. J Infect Dis 2009; 199:605-9.
4. Lodise TP, Graves J, Evans A, Graffunder E, Helmecke M, Lomaestro BM, et al. Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin. Antimicrob Agents Chemother 2008; 52:3315-20.
5. Maor Y, Hagin M, Belausov N, Keller N, Ben-David D, Rahav G. Clinical features of heteroresistant vancomycin-intermediate Staphylococcus aureus bacteremia versus those of methicillinresistant S. aureus bacteremia. J Infect Dis 2009; 199:619-24.
6. Soriano A, Marco F, Martinez JA, Pisos E, Almela M, Dimova VP, et al. Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis 2008; 46:193-200.
7. Holmes RL, Jorgensen JH. Inhibitory activities of 11 antimicrobial agents and bactericidal activities of vancomycin and daptomycin against invasive methicillin-resistant Staphylococcus aureus isolates obtained from 1999 through 2006. Antimicrob Agents Chemother 2008; 52:757-60.
8. Biedenbach DJ, Bell JM, Sader HS, Fritsche TR, Jones RN, Turnidge JD. Antimicrobial susceptibility of Gram-positive bacterial isolates from the Asia-Pacific region and an in vitro evaluation of the bactericidal activity of daptomycin, vancomycin, and teicoplanin: a SENTRY Program Report (2003-2004). Int J Antimicrob Agents 2007; 30:143-9.
9. Pfaller MA, Sader HS, Jones RN. Evaluation of the in vitro activity of daptomycin against 19615 clinical isolates of Gram-positive cocci collected in North American hospitals (2002-2005). Diagn Microbiol Infect Dis 2007; 57:459-65.
10. Sader HS, Moet G, Jones RN. Update on the in vitro activity of daptomycin tested against 17,193 Gram-positive bacteria isolated from European medical centers (2005-2007). J Chemother 2009; 21:500-6.
11. Picazo JJ, Betriu C, Culebras E, Rodriguez-Avial I, Gómez M, López F, and the VIRA study Group. Activity of daptomycin against staphylococci collected from bloodstream infections in Spanish medical centers. Diagn Microbiol Infect Dis 2009; 64:448-51.
12. Picazo JJ, Betriu C, Rodríguez-Avial I, Azahares E, Ali Sánchez B y Grupo VIRA. Vigilancia de resistencias a los antimicrobianos: estudio VIRA. Enferm Infecc Microbiol Clin 2002; 20:503-10.
13. Picazo JJ, Betriu C, Rodíguez-Avial I, Culebras E, Gómez M y Grupo VIRA. Vigilancia de resistencias a los antimicrobianos: estudio VIRA 2004. Enferm Infecc Microbiol Clin 2004; 22:517-25.
14. Picazo JJ, Betriu C, Rodriguez-Avial I, Culebras E, Gomez M, López F y Grupo VIRA. Vigilancia de resistencias a los antimicrobianos: estudio VIRA 2006. Enferm Infecc Microbiol Clin 2006; 24:617-28.
15. Picazo JJ, Betriu C, Rodríguez Avial I, Culebras E, López-Fabal F, Gómez M. and the VIRA Study Group. Comparative activities of daptomycin and several agents against staphylococcal blood isolates. Glycopeptide tolerance. Diagn Microbiol Infect Dis (en prensa).
16. Clinical and Laboratory Standards Institute. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard, 8th ed. vol 29, no. 2. CLSI document M07-A8. 2009. CLSI, Wayne, PA.
17. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. 20th informational supplement. vol. 30, no. 1, CLSI document M100-S20. 2010. CLSI, Wayne, P.A.
18. Morales G, Picazo JJ, Baos E, Candel FJ, Arribi A, Peláez B, et al. Resistance to linezolid is mediated by the cfr gene in the first report of an outbreak of linezolid-resistant Staphylococcus aureus. Clin Infect Dis 2010; 50:821-5.
19. Sader HS, Jones RN. Antimicrobial susceptibility of Gram-positive bacteria isolated from US medical centers: results of the Daptomycin Surveillance Program (2007-2008). Diagn Microbiol Infect Dis 2009; 65:158-62.
20. Sader HS, Becker HK, Moet GJ, Jones RN. Antimicrobial activity of daptomycin tested against Staphylococcus aureus with vancomycin MIC of 2 μg/mL isolated in the United States and European hospitals (2006-2008). Diagn Microbiol Infect Dis 2010; 66:329-31.
21. Anastasiou DM, Morgan M, Ruane PJ, Steenbergen JN, Katz BD, Alder JD, et al. In vitro activity of daptomycin against multidrug-resistant Staphylococcus aureus and S. aureus with known virulence factors, including community-acquired methicillin-resistant isolates. Diagn Microbiol Infect Dis 2008; 61:339-42.
22. Traczewski MM, Katz BD, Steenbergen JN, Brown SD. Inhibitory and bactericidal activities of daptomycin, vancomycin, and teicoplanin against methicillin-resistant Staphylococcus aureus isolates collected from 1985 to 2007. Antimicrob Agents Chemother 2009; 53:1735-8.